Charles Grassley

Jul 14 | Jeff Lagasse
An ongoing legal battle has made the price transparency final rule contentious, but its implementation may be inevitable.
Apr 08 | Jeff Lagasse
The data was gathered before COVID-19 began its spread across the globe, meaning the outlook for…
Mar 17 | Jeff Lagasse
The savings are due in part to strict price-reporting controls on pharmaceutical companies and…
Jan 10 | Susan Morse
Over $2.1 billion arose from lawsuits filed by whistleblowers under the qui tam provisions of the False Claims…
Dec 19, 2019 | Jeff Lagasse
In contrast, taxpayers would face additional costs if manufacturer rebates were directly…
Dec 16, 2019 | Susan Morse
The Senate Finance Committee's bill would cancel planned cuts to Medicaid disproportionate-share hospital payments for 2020 and 2021.
Apr 09, 2019 | Susan Morse
The rebate rule will not solve the drug affordability problem, PBM executives told the Senate Finance Committee.
Feb 26, 2019 | Susan Morse
End rebates for both Medicare and commercial plans, and they will lower list prices, pharmaceutical…
Feb 25, 2019 | Susan Morse
On Tuesday morning, executives from seven pharmaceutical companies will face ...
Consumer comparing prices with a pharmacist.
Aug 22, 2018 | Susan Morse
The amendment would give funding to the Department of Health and Human Services to require drug pricing in…